ArticleActa pharmaceutica Sinica. B2015
Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.
Article in Acta pharmaceutica Sinica. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Quantitative targeted proteomics for occult cancer screening in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study.Research and practice in thrombosis and haemostasis · 2025Article
- Evaluation of Kallistatin Levels in COPD Exacerbations.Canadian respiratory journal · 2025Article
- The multifaceted role of kallistatin in human diseases: mechanistic insights and translational potential.Frontiers in cardiovascular medicine · 2025Review
- Role of human Kallistatin in glucose and energy homeostasis in mice.Molecular metabolism · 2024Article
- Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease.Signal transduction and targeted therapy · 2024Article
- Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.International journal of molecular sciences · 2022Article
- Biodistribution Profile of Magnetic Nanoparticles in Cirrhosis-Associated Hepatocarcinogenesis in Rats by AC Biosusceptometry.Pharmaceutics · 2022Article
- Application of Nanomicelles in Enhancing Bioavailability and Biological Efficacy of Bioactive Nutrients.Polymers · 2022Review
- Serum kallistatin as a marker of severity of liver fibrosis in cirrhosis: A cross-sectional observational study.Journal of family medicine and primary care · 2022Article
- Lipid and renal profile in assessing the severity of alcoholic liver disease.Bioinformation · 2022Article
- Kallistatin correlates with inflammation in abdominal aortic aneurysm and suppresses its formation in mice.Cardiovascular diagnosis and therapy · 2020Article
- Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats.Acta pharmaceutica Sinica. B · 2020Article
- Reduced Plasma Kallistatin Is Associated With the Severity of Coronary Artery Disease, and Kallistatin Treatment Attenuates Atherosclerotic Plaque Formation in Mice.Journal of the American Heart Association · 2018Article
- Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression.Future science OA · 2018Review
- Cirrhosis of liver: Interference of serpins in quantification of SERPINA4 - A preliminary study.Practical laboratory medicine · 2017Article
- Kallistatin suppresses cancer development by multi-factorial actions.Critical reviews in oncology/hematology · 2017Review
- Observational
- Protective Role of Kallistatin in Vascular and Organ Injury.Hypertension (Dallas, Tex. : 1979) · 2016Review
- Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation.Glycoconjugate journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kallistatin, which protects organs and cells against inflammation, fibrosis and oxidative stress, is mainly synthesized and secreted in liver. However, its relationship to human liver disease remains unclear. The purpose of this study was to explore the relationship between serum kallistatin and clinical evidence of both cirrhosis and hepatocellular carcinoma (HCC), and to determine if serum kallistatin levels could be used as a diagnostic indicator of hepatic health status, especially human liver cirrhosis (LC). Our cohort consisted of 115 patients with clinically proven liver fibrosis (LF), LC, or HCC by liver biopsies, and 31 healthy controls (CON). Serum kallistatin levels were quantified by ELISA. Results of the present study demonstrated that irrespective of the underlying etiology, serum kallistatin levels were significantly lower in the LF/LC group when compared with the CON group. A decrease in serum kallistatin levels appeared to reflect the extent of cirrhosis, with the lowest levels associated with higher grades of cirrhosis. Patients with LC had a noticeable correlation between serum kallistatin levels and other serum biochemical indicators. The area under the curve (AUC) for LC, viral liver cirrhosis (VLC) and alcoholic liver cirrhosis (ALC) was 0.845, 0.757 and 0.931, respectively. In conclusion, our findings demonstrated that kallistatin, a plasma protein produced by the liver, can be a useful and reliable diagnostic indicator of hepatic health status, especially for LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.